Диссертация (1139687), страница 34
Текст из файла (страница 34)
Hardwick // Biochem Pharmacol. –2008. – Vol. 75. – P. 2263–2275.191. Harlow, G. R. Analysis of human cytochrome P450 3A4 cooperativity:construction and characterization of a site-directed mutant that displays hyperbolicsteroid hydroxylation kinetics / G. R. Harlow, J. R. Halpert // Proc Natl Acad Sci U S A.– 1998.
– Vol. 95 – P. 6636–6641.192. He, Y. A. Analysis of homotropic and heterotropic cooperativity ofdiazepam oxidation by CYP3A4 using site-directed mutagenesis and kinetic modeling /Y. A. He, F. Roussel, J. R. Halpert // Arch Biochem Biophys. – 2003. – Vol. 409 –P. 92–101.193. Hietenen, E. Influence of riboflavin deficiency on intestinal drugmetabolizing enzyme activities in rat / E.
Hietenen, U. Koivusari, A. Norling //Nutrition, Digestion, Metabolism, Advances in physiological sciences, Proceedings of213the 28th International Congress of Physiological Sciences, Budapest, 1980, Vol. 12 / ed.T. Gáti, L. G. Szollár, Gy. Ungváry. – Budapest: Pergamon Press, 1981. – P.89–93.194. Hollenberg, P. F. Mechanisms of cytochrome P450 and peroxidasecatalyzed xenobiotic metabolism / P. F. Hollenberg // FASEB J. – 1992. – Vol.
6 – N 2.– P. 686–694.195. Holtzman, J. L. The role of the stimulation of NADPH-cytochrome P- 450reductase activity in hepatic microsomal mixed function oxidase activity /J. L. Holtzman // Pharm. And Ther. – 1979. – Vol. 4. – N 3. – P. 601–627.196. Howell, S. R. Effects of Retinoid Treatment of Rats on HepaticMicrosomal Metabolism and Cytochromes P450 / S.
R. Howell, M. A. Shirley,E. H. Ulm // Drug Metabolism and Disposition. – 1998. – Vol. 26. – N 3. – P 234–239.197. Hrycay, E. G. Involvement of cytochrome P450 in reactive oxygen speciesformation and cancer / E. G. Hrycay, S. M. Bandiera // Cytochrome P450 function andpharmacological roles in inflammation and cancer, Advances in pharmacology, Vol. 74/ ed.
J. P. Hardwick – 1st ed. – San Diego: Academic Press, 2015. – Ch. 2. – P. 35–84.198. Hrycay, E. G. The monooxygenase, peroxidase, and peroxygenaseproperties of cytochrome P450 / E. G. Hrycay, S. M. Bandiera // Arch. Biochem.Biophys. – 2012. –Vol. 522. – N 2. – P. 71–89.199. Human Cytochrome P450 3A4 as a Biocatalyst: Effects of the EngineeredLinker in Modulation of Coupling Efficiency in 3A4-BMR Chimeras / D. Degregorio[et al.] // Frontiers in Pharmacology. – 2017. – Vol.
8 – Article 121.200. Huxtable, R. J. Physiological actions of taurine / R. J. Huxtable // PhysiolRev. – 1992. – Vol. 72 – P. 101–163.201. Identification of mutant Asp251Gly/Gln307His of cytochrome P450 BM3for the generation of metabolites of diclofenac, ibuprofen and tolbutamide /G. E. Tsotsou [et al.] // Chemistry. – 2012. – Vol. 18. – N. 12. – P. 3582–3588.202. Im, S.
The interaction of microsomal cytochrome P450 2B4 with its redoxpartners, cytochrome P450 reductase and cytochrome b5 / S. Im, L. Waskell // Arch.Biochem. Biophys. – 2011. – Vol. 507 – P. 144–153.214203. Improvement of insulin-stimulated glucose-disposal in type 2 diabetes afterrepeated parenteral administration of thioctic acid / S. Jacob [et al.] // Exp ClinEndocrinol Diabetes.
– 1996. – Vol. 104. – N 3. – P. 284–288.204. Influence of alpha-lipoic acid on intracellular glutathione in vitro and invivo / E. Busse [et al.] // Arzneimittelforschung. – 1992. – Vol. 42. – N 6. – P.829–831.205. Influence of food intake on the bioavailability of thioctic acid enantiomers /C. H. Gleiter [et al.] // Eur J Clin Pharmacol. – 1996. – Vol. 50. – N 6. – P. 513–514.206. Inhibitory effects of polyphenols on human cytochrome P450 3A4 and 2C9activity // Kimura, Y. [et al.] // Food and Chem Toxicol. – 2010. – Vol.
48. – P. 429–435.207. Inactivation of cytochrome P-450 by a troleandomycin metabolite.Protective role of glutathione. / D. Pessayre [et al.] // J Pharmacol Exp Ther. – 1983. –Vol. 224 – P. 685–691.208. Integrated in silico-in vitro strategy for addressing cytochrome P450 3A4time-dependent inhibition / M. Zientek [et al.] // Chem Res Toxicol.
– 2010. – Vol. 23.– N 3. – P. 664–676.209. Irbesartan and lipoic acid improve endothelial function and reduce markersof inflammation in the metabolic syndrome: results of the Irbesartan and Lipoic Acid inEndothelial Dysfunction (ISLAND) study / S. Sola [et al.] // Circulation. – 2005. –Vol.
111. – N 3. – P. 343–348.210. Isin, E. M. Substrate binding to cytochromes P450 / E. M. Isin,F. P. Guengerich // Anal Bioanal Chem. – 2008. – Vol. 392 – P. 1019–1030.211. Jain, K. K. Current status of molecular biosensors / K. K. Jain // MedDevice Technol. – 2003. – Vol. 14. – N 4. – P. 10–15.212. Jeong, J. The effect of electrode material on the generation of oxidants andmicrobial inactivation in the electrochemical disinfection processes / J.
Jeong, C. Kim,J. Yoon // Water Res. – 2009. – Vol. 43 – N 4. – P. 895–901.213. Jong, C. J. Mechanism underlying the antioxidant activity of taurine:prevention of mitochondrial oxidant production / C. J. Jong, J. Azuma, S. Schaffer //Amino Acids. – 2012. – Vol. 42 – P. 2223–2232.215214. Jonsson, K. H. Cytochrome P-455 nm complex formation in themetabolism of phenylalkylamines. XII. Enantioselectivity and temperature dependencein microsomes and reconstituted cytochrome P-450 systems from rat liver /K.
H. Jonsson, B. Lindeke // Chirality. – 1992. – Vol. 4. – P. 469–477.215. Karuzina, I. I. The oxidative inactivation of cytochrome P450 inmonooxygenase reactions / I. I. Karuzina, A. I. Archakov // Free radical biology andmedicine. – 1994. – Vol. 16. – P. 73–97.216. Kim, R. B. Drugs as P-glycoprotein substrates, inhibitors, and inducers /R. B. Kim // Drug Metab Rev. – 2002. – Vol. 34 – P. 47–54.217. Konrad, D. Utilization of the insulin-signaling network in the metabolicactions of alpha-lipoic acid-reduction or oxidation? / D. Konrad // Antioxid RedoxSignal. – 2005. – Vol.
7. – N 7–8. – P. 1032–1039.218. Kramer, K. R-alpha-lipoic acid / K. Kramer, L. Packer // Nutraceuticals inHealth and Disease Prevention / ed. K. Kramer, P. Hoppe, L. Packer. – New York:Marcel Dekker, Inc., 2001 – P. 129–164.219. Landes, N. Homologous metabolic and gene activating routes forvitamins E and K / N. Landes, M. Birringer, R.
Brigelius-Flohé // Mol Aspects Med. –2003. – Vol. 24 – P. 337–344.220. León-Cachón, R. B. Individual response to drug therapy: bases and studyapproaches / R. B. León-Cachón, J. A. Ascacio-Martínez, H. A. Barrera-Saldaña // RevInvest Clin. – 2012. – Vol. 64. – N 4. – P. 364–376.221. Lewis, D. Guide to Cytochrome P450.
Structure and function / D. Lewis. –London, New York: Taylor and Francis Eds., 2001. – 240 p.222. Lia, Y. Gold nanoparticle-based biosensors / Y. Lia, H. J. Schluesenerb,S. Xua // Gold Bull. – 2010. – Vol. 43 – P. 29–41.223. Lipoic acid affects cellular migration into the central nervous system andstabilizes blood-brain barrier integrity / G. Schreibelt [et al.] // J Immunol.
–2006. –Vol. 177. – N 4. – P. 2630–2637.216224. Lipoic acid stimulates cAMP production in T lymphocytes and NK cells /R. V. Schillace [et al.] // Biochem Biophys Res Commun. – 2007. – Vol. 354. – N 1. –P. 259–264.225. Lipoic acid as a potential therapy for chronic diseases associated withoxidative stress / A. R. Smith [et al.] // Curr Med Chem. – 2004. – Vol. 11. – N 9.
–P. 1135–1146.226. Lipoic acid in multiple sclerosis: a pilot study / V. Yadav [et al.] // MultScler. –2005. – Vol. 11. – N 2. – P. 159–165.227. Lipoic acid stimulates cAMP production via G protein coupled receptordependent and independent mechanisms / S. Salinthone [et al.] // J Nutr Biochem. –2011. – Vol. 22. – N 7. – P. 681–690.228. Liu, S. Application of colloidal gold in protein immobilization, electrontransfer, and biosensing /S. Liu, D.
Leech, H. Ju // Anal. Lett. – 2003. – Vol. 36. – N 1.– P. 1–19.229. Lu, A. Y. Role of hemoprotein P-450 in fatty acid omega-hydroxylation ina soluble enzyme system from liver microsomes / A. Y. Lu, M. J. Coon // J. Biol. Chem.– 1968. – Vol. 243. – N 6. – P. 1331–1332.230. Lu, A. Y. H. The 1996 Bernard B. Brodie Lecture. A journey incytochrome P450 and drug metabolism research / Anthony Y. H. Lu // Drug Metab.Dispos.
– 1998. – Vol. 26. – N 12. – P. 1168–1173.231. Luthra,A. Spectroscopicfeatures of cytochrome P450 reactionintermediates /A. Luthra, I. G. Denisov, S. G. Sligar // Arch Biochem Biophys. – 2011.– Vol. 507. – N 1. – P. 26–35.232. Marcinkiewicz, J. Taurine bromamine: a new therapeutic option ininflammatory skin diseases / J. Marcinkiewicz // Pol Arch Med Wewn. – 2009. –Vol. 119.
– N 10. – P. 673–676.233. Marcoff, L. The role of coenzyme Q10 in statin-associated myopathy: asystematic review / Marcoff, L., Thompson P. // J Am Coll Cardiol. – 2007. – Vol. 49. –N 4. – P. 2231–2237.234. Martinho, M.57217Fe Mössbauer spectroscopy in chemistry and biology /M. Martinho, E. Münck // Physical Inorganic Chemistry Principles Methods andModels / ed. A. Bakac. – New York: John Wiley & Sons, Inc., 2010. – P. 39–67.235. Martin, J. Cytochrome P450 drug interactions within the HMG–CoAreductase inhibitor class: are they clinically relevant? / J. Martin, H.
Krum // Drug Saf2003. – Vol. 26 – P. 13–21.236. Masters, B. E. The history, properties and function of NADPH-cytochromeP-450 reductase / B. E. Masters, R. T. Okita // Pharm. And Ther. – 1980. – Vol. 9. –N 2. – P. 227–244.237. Matsui, S. Genomic Biomarkers for Personalized Medicine: Developmentand Validation in Clinical Studies / S. Matsui // Computational and MathematicalMethods in Medicine — 2013. – Vol. 2013 – Art.ID 865980 – 9 p.238.
May, J. M. Protection and recycling of alpha-tocopherol in humanerythrocytes by intracellular ascorbic acid / J. M. May, Z. C. Qu, S Mendiratta // ArchBiochem Biophys. – 1998. – Vol. 349. – N 2. – P. 281–289.239. Memory loss in old rats is associated with brain mitochondrial decay andRNA/DNA oxidation: partial reversal by feeding acetyl-L-carnitine and/or R-alphalipoic acid / J. Liu [et al.] // Proc Natl Acad Sci U S A. – 2002.
– Vol. 99. – N 4. –P. 2356–2361.240. Metabolism of sulfinpyrazone sulfide and sulfinpyrazone by human livermicrosomes and cDNA-expressed cytochrome P450s / M. He [et al.] // Drug MetabDispos. – 2001. – Vol. 29 – P. 701–711.241. Meunier, B. Mechanism of oxidation reactions catalyzed by cytochromep450 enzymes /B. Meunier, S. P. de Visser, S. Shaik // Chem Rev. –2004. – Vol. 104. –N 9. – P. 3947–3980.242. Microsomes and Drug Oxidations / ed. J. R. Gillette, A. H. Conney,G. J. Cosmides. – New York: Academic, 1969. – 547 p.243. Miyazawa, M. Oxidation of 1,8-cineole, the monoterpene cyclic etheroriginated from eucalyptus polybractea, by cytochrome P450 3A enzymes in rat and218human liver microsomes / M.
![](https://s.studizba.com/z.php?f=/templates/si/i/noavatar.png&w=100&h=100&t=1"){kind=avatar}
